ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The development of tyrosine kinase inhibitors (TKIs), such as imatinib, inhibiting the activity of the BCR-ABL1 tyrosine kinase, represented a significant breakthrough in CML treatment.